Identification of Factors Causing Sudden Coagulation in Patients with Acute Myocardial Infarction

Arnaldo Pinelli1, S. Trivulzio1, S. Brenna1, V. Rosato1, L. Rivoltini1 and G. Rossoni1

1Department of Medical Biotechnology and Translational Medicine, University of Milan, Italy
2Laboratory of Clinical Chemistry, Ospedale Niguarda Ca’ Granda, Milan, Italy
3Department of Clinical Science and Community, Milan, Italy
4IRCCS Foundation National Institute of Cancer, Milan, Italy

Abstract

Background: Coronary artery disease (CAD) evolving to acute myocardial infarction (AMI) is due to the thrombotic occlusion of coronary vessels in the presence of destabilized atheroma, rich in inflammatory cells secreting proteolytic enzymes that induce the development of thrombosis. The aim of this study was to analyse the plasma of AMI patients for the detection of proteases or factors that may cause fast coagulation.

Methods: The patients were analysed for the presence of plasma of cardiac troponin T (c-TnT) or proteases as neutrophil gelatinase-associated lipocalin (NGAL) using ELISA method and matrix metalloproteinase-9 (MMP-9) utilising flow cytometry technique and interleukin-8 (IL-8) using flow cytometry methodology.

Results: The presence of AMI was demonstrated by high levels of c-TnT; in comparison with controls the AMI patients displayed a significant increase in the values of MMP-9 and low levels of antithrombin III: these markers were negatively correlated: MMP-9 appeared to cause the coagulation activity documented by the consumption of antithrombin III. The same patients also showed high levels of NGAL, which is known to modulate MMP-9 activity and to be involved in coagulation process; patients also exhibited an increased amount of IL-8 which appears to be associated with high levels of NGAL: this cytokine seems to affect the values of NGAL which is linked to coagulation process.

Conclusion: The high levels of MMP-9, NGAL and IL-8 in AMI patients seemed to be interrelated and connected with the process leading to rapid coagulation. These markers may be measured in absence of AMI, particularly in CAD patients, as their detection may reveal a risk of sudden coronary coagulation.

Keywords: Acute Myocardial Infarction (AMI); Coronary Artery Diseases (CAD); Unstable atherosclerotic plaque; Matrix Metalloproteinase-9 (MMP-9); Neutrophil Gelatinase-Associated Lipocalin (NGAL); Interleukin-8 (IL-8)

Introduction

Coronary artery disease (CAD) evolving to acute myocardial infarction (AMI) is associated with the thrombotic occlusion of coronary vessels in the presence of atheromatous plaque [1]. The atheroma is rich in inflammatory cells secreting proteolytic enzymes that may erode the fibrous cap and facilitate its rupture (unstable plaque) [2], and induce the development of coagulation and thrombosis [3].

It can be hypothesised that these secreted proteases such as matrix metalloproteinase-9 (MMP-9) [2], gelatinases such as neutrophil gelatinase-associated lipocalin (NGAL) [4], and cytokines such as IL-8 [5] may be involved in the sudden coagulation process: their proteolytic activity may activate the development of thrombosis observed in acute myocardial infarction.

The aim of this study was to analyse the plasma of healthy subjects and AMI patients for the detection of proteases that may cause fast coagulation, in particular MMP-9, NGAL and the interleukin IL-8.

Patients and Methods

Eight randomly selected male AMI patients aged 50-65 years and eight healthy male subjects of the same age were selected in order to verify whether these markers are interrelated in priming the coagulation and thrombosis that leads to AMI. This preliminary study was approved by the Ethical Committee of Niguarda Ca’ Granda Hospital Milan – Italy.

The presence of AMI was demonstrated by measuring the specific marker c-TnT [6] and the plasma levels were evaluated using a commercial kit provided by Roche (Milan, Italy) [6].

MMP-9 and IL-8 were assayed using a BenderMed System flow cytomix simplex kits given by Prodotti Gianni (Milan, Italy), which were selected as representative examples of technologies currently used for high-throughput immunoanalysis [7]. NGAL was analysed using an enzyme-linked immunosorbent assay (ELISA) [8] supplied by Bioparto Diagnostic (Verona, Italy) in accordance with the manufacturer’s instructions. Plasma antithrombin III was measured using colorimetric method, based on a chromogenic substrate: S-2765-N-Z-D-ARG-GLY-ARG-pNA using a kit provided by Instrumentation Laboratory (Milan, Italy) [9].

Statistical analysis

The values of the various biochemical markers, in the plasma of normal subjects and AMI patients, were compared using Kruskal-Wallis test and the significance of differences (P) was calculated [10,11].

*Corresponding author: Professor Arnaldo Pinelli, Department of Medical Biotechnology and Translational Medicine, Via Vanvitelli 32, 20129 - Milan, Italy. Tel: +39 02 50317086; Fax: +39 02 50316949; E-mail: arnaldo.pinelli@unimi.it

Received April 03, 2012; Accepted June 22, 2012; Published June 25, 2012


Copyright: © 2012 Pinelli A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The correlations between MMP-9 and antithrombin III or IL-8 and NGAL were calculated using Spearman’s correlation coefficient [10,11].

Results

Table 1 shows the plasma values of c-TnT (ng/ml) observed in healthy subjects (<0.01) and AMI patients (3.20) with highly significant difference: P<0.001. c-TnT is a specific marker of AMI and clearly demonstrates the presence of AMI.

Table 1 reports the plasma values of MMP-9, antithrombin III, NGAL and IL-8 expressed as median and their significance calculated with Kruskal-Wallis test.

In particular the plasma levels of MMP-9 (ng/ml) observed in healthy subjects (29.25) and in AMI patients (32.35) exhibited significantly different values: P<0.034. The MMP-9 detected in plasma may affect biochemical process.

The levels of antithrombin III (ng/ml) detected in healthy subjects (109.50) and AMI patients (96.00) appear to be significantly different: P<0.004.

The values of NGAL (ng/ml) detected in healthy subjects (67.00) and AMI patients (157.00) differ very significantly: P<0.004. The high increase of NGAL in AMI patients suggests a role of this marker in myocardial damage.

The values of IL-8 (pg/ml) observed in healthy subjects (11.82) and AMI patients (27.30) were significantly different: P<0.027. The increase of IL-8 suggests a role of this inflammatory marker in myocardial infarction.

The Spearman correlation between MMP-9 and antithrombin III appears to be significant (r=-0.523; P=0.05).

Discussion

The occurrence of AMI was demonstrated by high levels of the specific c-TnT marker [6] (Table 1). Remarkably, in the AMI patients, affected by acute coronary coagulation, were found, altered plasma values of MMP-9, antithrombin III, NGAL and IL-8. It appears to be quite important to analyse the links between these altered factors and the priming of coagulation. The AMI patients had higher MMP-9 levels than the controls. In addition, they had lower amount of antithrombin III, which is consumed by coagulation [12] and the lowering of antithrombin III during AMI or unstable angina was reported also by other authors [12,13]. Significant negative correlation between MMP-9 and antithrombin III (r=-0.523; P=0.05; Spearman correlation) suggests that the former affected the levels of the latter and promoted coagulation. The process of coagulation is activated by MMP-9, which may be also attributed to inflammatory cells infiltrating atherosclerotic plaque [1-3,14].

We suggest that the markers MMP-9, NGAL and IL-8 found in AMI subjects and associated with sudden coagulation may be used in a large-scale study of CAD patients to reveal a risk of acute coronary syndrome.

Table 1: Plasma markers detected in healthy subjects (controls) and acute myocardial infarction patients (AMI). Each value represents the median value of eight subjects. The significance P values calculated with Kruskal-Wallis test are reported.

<table>
<thead>
<tr>
<th></th>
<th>cTnT</th>
<th>MMP-9</th>
<th>Antithrombin III</th>
<th>NGAL</th>
<th>IL-8</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ng/ml</td>
<td>ng/ml</td>
<td>mg/dl</td>
<td>ng/ml</td>
<td>pg/ml</td>
</tr>
<tr>
<td>Controls</td>
<td>0.01</td>
<td>29.25</td>
<td>109.50</td>
<td>87.00</td>
<td>13.82</td>
</tr>
<tr>
<td>AMI</td>
<td>3.20</td>
<td>32.35</td>
<td>96.00</td>
<td>157.00</td>
<td>27.30</td>
</tr>
<tr>
<td>Significance</td>
<td>P&lt;0.001</td>
<td>P&lt;0.034</td>
<td>P&lt;0.004</td>
<td>P&lt;0.004</td>
<td>P&lt;0.027</td>
</tr>
<tr>
<td>Kruskal-Wallis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Acknowledgements

This study is dedicated to the memory of Professor Cirillo Mussini (17.02.1936 – 17.03.2007), the Founder and first President of the Concorde Group (Spiezzano, Modena, Italy).

The authors are grateful to Doctor Luca Mussini, Managing Director to Concorde Group S.p.A. (Spiezzano, Modena, Italy) for encouraging and funding this study.
Conflict of Interest

None of the authors have any conflict of interest in relation to this manuscript.

References


9. Antithrombin: automated chromogenic assay for the quantitative determination of antithrombin in human citrated plasma on the IL coagulation systems. Instrumentation Laboratory, Milan.


